JP2021528047A5 - - Google Patents
Info
- Publication number
- JP2021528047A5 JP2021528047A5 JP2020562110A JP2020562110A JP2021528047A5 JP 2021528047 A5 JP2021528047 A5 JP 2021528047A5 JP 2020562110 A JP2020562110 A JP 2020562110A JP 2020562110 A JP2020562110 A JP 2020562110A JP 2021528047 A5 JP2021528047 A5 JP 2021528047A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antigen
- polypeptide sequence
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668427P | 2018-05-08 | 2018-05-08 | |
| US62/668,427 | 2018-05-08 | ||
| US201862754207P | 2018-11-01 | 2018-11-01 | |
| US62/754,207 | 2018-11-01 | ||
| US201962787815P | 2019-01-03 | 2019-01-03 | |
| US62/787,815 | 2019-01-03 | ||
| PCT/US2019/029888 WO2019217145A1 (en) | 2018-05-08 | 2019-04-30 | Anti-dll3 antibodies and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021528047A JP2021528047A (ja) | 2021-10-21 |
| JP2021528047A5 true JP2021528047A5 (https=) | 2022-05-02 |
| JPWO2019217145A5 JPWO2019217145A5 (https=) | 2022-05-02 |
| JP7455388B2 JP7455388B2 (ja) | 2024-03-26 |
Family
ID=68467536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562110A Active JP7455388B2 (ja) | 2018-05-08 | 2019-04-30 | 抗ｄｌｌ３抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12037391B2 (https=) |
| EP (1) | EP3790586A4 (https=) |
| JP (1) | JP7455388B2 (https=) |
| KR (1) | KR102922314B1 (https=) |
| CN (2) | CN112584860B (https=) |
| AU (1) | AU2019267349B2 (https=) |
| BR (1) | BR112020021280A2 (https=) |
| CA (1) | CA3097193A1 (https=) |
| IL (1) | IL278466B1 (https=) |
| MX (1) | MX2020011914A (https=) |
| SG (1) | SG11202009772PA (https=) |
| WO (1) | WO2019217145A1 (https=) |
| ZA (1) | ZA202006318B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3132202A1 (en) * | 2019-04-08 | 2020-10-15 | Phanes Therapeutics, Inc. | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
| CA3160436A1 (en) * | 2019-12-17 | 2021-06-24 | Jack Chongyang LI | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof |
| AU2022217274A1 (en) * | 2021-02-05 | 2023-07-27 | Phanes Therapeutics, Inc. | Bispecific antibodies with charge pairs and uses thereof |
| CN117529337A (zh) * | 2021-05-08 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 针对dll3的结合分子及其应用 |
| CN116271079B (zh) * | 2021-07-30 | 2025-11-14 | 上海复旦张江生物医药股份有限公司 | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 |
| KR20240040090A (ko) * | 2021-07-30 | 2024-03-27 | 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 | 항-dll3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도 |
| MX2024003331A (es) * | 2021-09-17 | 2024-06-19 | Wuxi Biologics Ireland Ltd | Moleculas de union a d3 y usos de estas. |
| TW202346346A (zh) * | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途 |
| CN114292334B (zh) * | 2021-12-24 | 2023-11-17 | 杭州贤至生物科技有限公司 | 抗可替宁特异性抗体、质粒载体及方法 |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| CN116789836B (zh) * | 2023-08-14 | 2024-01-05 | 浙江时迈药业有限公司 | 针对dll3的抗体及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2844519A1 (fr) * | 2002-09-17 | 2004-03-19 | Bio Merieux | Proteine recombinante chimerique et diagnostic in vitro |
| WO2007080597A2 (en) | 2006-01-16 | 2007-07-19 | Compugen Ltd. | Polynucleotide and polypeptide sequences and methods for diagnosis |
| US20120042416A1 (en) * | 2009-08-24 | 2012-02-16 | Fraunhofer-Gesellschaft zur Forderung der angewandten e.V. | Antibody fusion-mediated plant resistance against Oomycota |
| JP2013507378A (ja) * | 2009-10-09 | 2013-03-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途 |
| EP3907242A1 (en) | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| CN103003697A (zh) * | 2010-05-17 | 2013-03-27 | 得克萨斯系统大学董事会 | 来自动物的单克隆抗体的快速分离 |
| PE20190658A1 (es) * | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| BR112015019909A2 (pt) | 2013-02-22 | 2017-08-29 | Abbvie Stemcentrx Llc | Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit |
| PE20160209A1 (es) * | 2013-08-28 | 2016-05-09 | Stemcentrx Inc | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso |
| PE20161209A1 (es) | 2014-02-21 | 2016-11-10 | Abbvie Stemcentrx Llc | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| MA41645A (fr) | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| US20190048094A1 (en) * | 2016-02-24 | 2019-02-14 | Oncomed Pharmaceuticals, Inc. | Redirecting immune responses |
| JP2019516705A (ja) | 2016-05-20 | 2019-06-20 | アッヴィ・ステムセントルクス・エル・エル・シー | 神経内分泌移行のリスクのある腫瘍を治療するための抗ｄｌｌ３薬物コンジュゲート |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7262440B2 (ja) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US20190225685A1 (en) | 2018-01-24 | 2019-07-25 | Abbvie Stemcentrx Llc | Anti-dll3 antibody drug conjugates and methods of use |
| US20220025037A1 (en) | 2018-04-03 | 2022-01-27 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
-
2019
- 2019-04-30 CA CA3097193A patent/CA3097193A1/en active Pending
- 2019-04-30 EP EP19800438.4A patent/EP3790586A4/en active Pending
- 2019-04-30 CN CN201980031386.3A patent/CN112584860B/zh active Active
- 2019-04-30 BR BR112020021280-6A patent/BR112020021280A2/pt unknown
- 2019-04-30 JP JP2020562110A patent/JP7455388B2/ja active Active
- 2019-04-30 WO PCT/US2019/029888 patent/WO2019217145A1/en not_active Ceased
- 2019-04-30 SG SG11202009772PA patent/SG11202009772PA/en unknown
- 2019-04-30 CN CN202410395728.2A patent/CN118146372A/zh active Pending
- 2019-04-30 AU AU2019267349A patent/AU2019267349B2/en active Active
- 2019-04-30 KR KR1020207034344A patent/KR102922314B1/ko active Active
- 2019-04-30 MX MX2020011914A patent/MX2020011914A/es unknown
- 2019-04-30 US US15/733,747 patent/US12037391B2/en active Active
-
2020
- 2020-10-12 ZA ZA2020/06318A patent/ZA202006318B/en unknown
- 2020-11-03 IL IL278466A patent/IL278466B1/en unknown
-
2024
- 2024-06-04 US US18/733,287 patent/US12325745B2/en active Active
-
2025
- 2025-04-29 US US19/193,538 patent/US20250257127A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021528047A5 (https=) | ||
| JP2021514664A5 (https=) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| CN101970497B (zh) | 抗‑EpCAM抗体及其用途 | |
| JP2021516057A5 (https=) | ||
| JPWO2019173420A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JPWO2019224711A5 (https=) | ||
| JP2021526022A5 (https=) | ||
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| CN116731180A (zh) | 抗ror1抗体及其制备和使用方法 | |
| JP2022526420A5 (https=) | ||
| JPWO2019173291A5 (https=) | ||
| JP2022527173A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2021517459A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| BR112020001657A2 (pt) | Anticorpo contra cd147 humana, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso do anticorpo ou do fragmento de ligação a antígeno,polinucleotídeo, vetor de expressão, célula hospedeira, método para produzir o anticorpo ou o fragmento de ligação a antígeno do mesmo, para prognosticar aresponsividade ao tratamento contra o câncer e para selecionar sujeitos para o tratamento contra o câncer, kit para determinar a responsividade ao tratamento contra o câncer, complexo de anticorpo-fármaco, e, anticorpo biespecífico | |
| JP2022526841A5 (https=) | ||
| JP2021512652A5 (https=) | ||
| CN109912716B (zh) | 一种egfr抗体及其制备方法和应用 |